beigene
IR Menu

Press Releases

Dec 15, 2018
BeiGene Announces Updated Phase 1A/1B Data on Tislelizumab Presented at the European Society for Medical Oncology Immuno-Oncology Congress    read more...
Dec 10, 2018
BeiGene to Present Clinical Data on Anti-PD-1 Antibody Tislelizumab at the European Society for Medical Oncology Immuno-Oncology Congress    read more...
Dec 05, 2018
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)    read more...
Dec 03, 2018
BeiGene Presents Clinical Results of Tislelizumab in Relapsed/Refractory Classical Hodgkin’s Lymphoma at the 60th American Society of Hematology Annual Meeting    read more...
Dec 01, 2018
BeiGene Announces Clinical Results of Zanubrutinib in Mantle Cell Lymphoma From Two Presentations at the 60th American Society of Hematology Annual Meeting    read more...
Nov 28, 2018
Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ Platforms Globally    read more...
Nov 20, 2018
BeiGene to Present at the 30th Annual Piper Jaffray Healthcare Conference    read more...
Nov 16, 2018
BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology    read more...
Nov 15, 2018
Priority Review Granted to BeiGene’s New Drug Applications for Zanubrutinib and Tislelizumab in China    read more...
Nov 13, 2018
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)    read more...
Nov 07, 2018
BeiGene Reports Third Quarter 2018 Financial Results    read more...
Nov 07, 2018
BeiGene Initiates Global Head-to-Head Phase 3 Clinical Trial of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma    read more...
Nov 05, 2018
BeiGene to Present Clinical Data on PARP Inhibitor Pamiparib at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology    read more...
Nov 01, 2018
BeiGene to Present Clinical Data on Tislelizumab and Zanubrutinib at the 60th American Society of Hematology Annual Meeting    read more...
Oct 24, 2018
BeiGene Announces Acceptance of its New Drug Application in China and Top-Line Pivotal Data for Zanubrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma    read more...
Oct 22, 2018
BeiGene Presents Preliminary Clinical Data on PARP Inhibitor Pamiparib in Combination with Low-Dose Temozolomide in Patients with Solid Tumors at European Society for Medical Oncology (ESMO) 2018 Congress    read more...
Oct 12, 2018
BeiGene Announces Updated Results from Phase 1 Clinical Trial of Zanubrutinib in Patients with Waldenström’s Macroglobulinemia    read more...
Oct 12, 2018
MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies    read more...
Oct 10, 2018
BeiGene Announces National Reimbursement Inclusion of VIDAZA® (Azacitidine for Injection) by the State Medical Insurance Administration in China    read more...
Oct 08, 2018
BeiGene to Present Clinical Data on Zanubrutinib and Pamiparib at Upcoming Medical Meetings    read more...